Amgen's Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease ...

Tests in 1,225 patients with the most deadly form of skin cancer reveal for the first time a genetic trait among most of ...

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control ...

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without ...

Drugs that boost the body’s immune system to fight disease are showing promise in treating a variety of cancers in earlier ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths ...

A new study found the drug kept head and neck cancers at bay for five years compared to 30 months with standard care ...

Results from a phase 3 clinical trial published in the New England Journal of Medicine, today (June 2nd) show that patients ...

Investigators evaluated the effectiveness of an immunotherapy in combination with standard radiation therapy for patients with intermediate-high risk localized prostate cancer.

Head and neck cancer patients went disease-free for five years, compared to half that time for people undergoing standard ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.